Filing Details

Accession Number:
0001179110-13-000738
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-01-09 17:30:46
Reporting Period:
2013-01-07
Filing Date:
2013-01-09
Accepted Time:
2013-01-09 17:30:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
792977 Amag Pharmaceuticals Inc. AMAG Pharmaceutical Preparations (2834) 042742593
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1537668 G Christopher White 100 Hayden Avenue
Lexington MA 02421
Chief Business Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2013-01-07 4,000 $16.07 2,000 No 4 S Direct
Common Stock Acquisiton 2013-01-07 4,000 $0.00 6,000 No 4 M Direct
Common Stock Disposition 2013-01-08 3,000 $15.87 3,000 No 4 S Direct
Common Stock Disposition 2013-01-09 3,000 $15.80 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Acquisiton 2013-01-07 4,000 $0.00 4,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
4,000 No 4 M Direct
Footnotes
  1. The sale reported on this Form 4 was effected pursuant to a 10b5-1 plan adopted by the reporting person.
  2. The shares sold on this date were sold in multiple transactions. The price reflected is the weighted average sales price per share of all shares sold under this reporting event on this date. The actual sales prices per share range from $15.79-$16.24. Upon request by the Securities and Exchange Commission, AMAG Pharmaceuticals, Inc. (the "Issuer"), or any security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each price.
  3. The shares were acquired by the reporting person as a result of the partial vesting of the restricted stock unit grant described below.
  4. Not applicable.
  5. The shares sold on this date were sold in multiple transactions. The price reflected is the weighted average sales price per share of all shares sold under this reporting event on this date. The actual sales prices per share range from $15.69-$16.08. Upon request by the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each price.
  6. The shares sold on this date were sold in multiple transactions. The price reflected is the weighted average sales price per share of all shares sold under this reporting event on this date. The actual sales prices per share range from $15.52-$16.04. Upon request by the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each price.
  7. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
  8. Grant of restricted stock unit pursuant to the Issuer's Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in three installments as follows: 50% on January 7, 2012, 25% on January 7, 2013 and the remaining 25% on January 7, 2014.